OBJECTIVE: We evaluated the expression of human trophoblast cell surface marker (Trop-2) in endometrial endometrioid carcinoma (EEC) and the potential application of hRS7, a humanized monoclonal anti-Trop-2 antibody, as a therapeutic agent against poorly differentiated EEC. METHODS: Trop-2 expression was evaluated by immunohistochemistry in 131 EEC with different degrees of differentiation and 32 normal endometrial controls (NEC). Trop-2 expression was also evaluated by quantitative real-time polymerase chain reaction and flow cytometry in 3 primary EEC cell lines derived from patients harboring poorly differentiated EEC. Finally, the sensitivity of grade 3 EEC cell lines to hRS7 antibody-dependent cellular cytotoxicity was tested in standard 5-hour Cr release assays. RESULTS: Trop-2 expression was detected in 126 (96.2%) of 131 EEC samples. Tumor tissues showed markedly increased Trop-2 positivity compared with NEC (P = 0.001). Trop-2 expression was significantly higher in all grades of EEC versus NEC. Grade 3 tumors displayed significantly stronger Trop-2 immunostaining compared with grade 1 EEC (P = 0.01). High Trop-2 expression by quantitative real-time polymerase chain reaction and flow cytometry was found in 1 grade 3 EEC primary cell line (EEC-ARK-1). Unlike Trop-2-negative EEC cell lines, EEC-ARK-1 was found highly sensitive to hRS7-mediated antibody-dependent cellular cytotoxicity in vitro (range of killing, 33.9%-50.6%; P = 0.004). Human serum did not significantly inhibit hRS7-mediated cytotoxicity against EEC-ARK-1 (P = 0.773). CONCLUSIONS: Trop-2 is highly expressed in EEC, and its expression is significantly higher in poorly differentiated EEC when compared with well-differentiated EEC. Primary grade 3 EECs overexpressing Trop-2 are highly sensitive to hRS7-mediated cytotoxicity in vitro. hRS7 may represent a novel therapeutic agent for the treatment of high-grade EEC refractory to standard treatment modalities.
OBJECTIVE: We evaluated the expression of human trophoblast cell surface marker (Trop-2) in endometrial endometrioid carcinoma (EEC) and the potential application of hRS7, a humanized monoclonal anti-Trop-2 antibody, as a therapeutic agent against poorly differentiated EEC. METHODS:Trop-2 expression was evaluated by immunohistochemistry in 131 EEC with different degrees of differentiation and 32 normal endometrial controls (NEC). Trop-2 expression was also evaluated by quantitative real-time polymerase chain reaction and flow cytometry in 3 primary EEC cell lines derived from patients harboring poorly differentiated EEC. Finally, the sensitivity of grade 3 EEC cell lines to hRS7 antibody-dependent cellular cytotoxicity was tested in standard 5-hour Cr release assays. RESULTS:Trop-2 expression was detected in 126 (96.2%) of 131 EEC samples. Tumor tissues showed markedly increased Trop-2 positivity compared with NEC (P = 0.001). Trop-2 expression was significantly higher in all grades of EEC versus NEC. Grade 3 tumors displayed significantly stronger Trop-2 immunostaining compared with grade 1 EEC (P = 0.01). High Trop-2 expression by quantitative real-time polymerase chain reaction and flow cytometry was found in 1 grade 3 EEC primary cell line (EEC-ARK-1). Unlike Trop-2-negative EEC cell lines, EEC-ARK-1 was found highly sensitive to hRS7-mediated antibody-dependent cellular cytotoxicity in vitro (range of killing, 33.9%-50.6%; P = 0.004). Human serum did not significantly inhibit hRS7-mediated cytotoxicity against EEC-ARK-1 (P = 0.773). CONCLUSIONS:Trop-2 is highly expressed in EEC, and its expression is significantly higher in poorly differentiated EEC when compared with well-differentiated EEC. Primary grade 3 EECs overexpressing Trop-2 are highly sensitive to hRS7-mediated cytotoxicity in vitro. hRS7 may represent a novel therapeutic agent for the treatment of high-grade EEC refractory to standard treatment modalities.
Authors: R Stein; S V Govindan; M J Mattes; L B Shih; G L Griffiths; H J Hansen; D M Goldenberg Journal: Clin Cancer Res Date: 1999-10 Impact factor: 12.531
Authors: L Zhang; W Zhou; V E Velculescu; S E Kern; R H Hruban; S R Hamilton; B Vogelstein; K W Kinzler Journal: Science Date: 1997-05-23 Impact factor: 47.728
Authors: Joyce Varughese; Emiliano Cocco; Stefania Bellone; Maria de Leon; Marta Bellone; Paola Todeschini; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin Journal: Cancer Date: 2011-01-18 Impact factor: 6.860
Authors: S Miotti; S Canevari; S Ménard; D Mezzanzanica; G Porro; S M Pupa; M Regazzoni; E Tagliabue; M I Colnaghi Journal: Int J Cancer Date: 1987-03-15 Impact factor: 7.396
Authors: Chanhee Han; Stefania Bellone; Peter E Schwartz; Serengulam V Govindan; Robert M Sharkey; David M Goldenberg; Alessandro D Santin Journal: Gynecol Oncol Rep Date: 2018-05-23
Authors: Sabina Sanegre; Núria Eritja; Carlos de Andrea; Juan Diaz-Martin; Ángel Diaz-Lagares; María Amalia Jácome; Carmen Salguero-Aranda; David García Ros; Ben Davidson; Rafel Lopez; Ignacio Melero; Samuel Navarro; Santiago Ramon Y Cajal; Enrique de Alava; Xavier Matias-Guiu; Rosa Noguera Journal: Front Cell Dev Biol Date: 2021-06-03